Literature DB >> 24363114

Distal dissection in total mesorectal excision, and preoperative chemoradiotherapy and lateral lymph node dissection for rectal cancer.

Jin-ichi Hida1, Kiyotaka Okuno, Tadao Tokoro.   

Abstract

The local recurrence rate after total mesorectal excision (TME) appears to be markedly lower than that after conventional operations. We reviewed all relevant articles identified from the MEDLINE databases and clarified the rationale for TME. It is clear that distal intramural spread is rare. Even when present, such spread is not likely to extend beyond 2 cm. Data with attention to mesorectal cancer deposits suggest that mesorectal clearance of at least 4-5 cm distal to the tumor should be sufficient. TME should be performed for most tumors of the mid- and lower rectum. This does not mean that the gut tube needs to be divided at the same level in every case. Dissection of the distal mesorectum off the gut tube can be performed, so the distal line of division of the bowel wall can be made at a minimum of 2 cm below the tumor if such a maneuver would ensure that the sphincters are preserved. In cases with cancer in the upper third of the rectum, the mesorectum and gut tube can safely be divided 5 cm below the tumor without jeopardizing the recurrence rates. Our findings indicate that TME is an essential treatment approach for rectal cancer, and lateral lymph node dissection and preoperative chemoradiotherapy are additional therapies that should be considered for advanced rectal cancer.

Entities:  

Mesh:

Year:  2013        PMID: 24363114     DOI: 10.1007/s00595-013-0811-2

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  126 in total

1.  Prognostic significance of radial margins of clearance in rectal cancer.

Authors:  D F de Haas-Kock; C G Baeten; J J Jager; J A Langendijk; L J Schouten; A Volovics; J W Arends
Journal:  Br J Surg       Date:  1996-06       Impact factor: 6.939

2.  Local recurrence after mesorectal excision for rectal cancer.

Authors:  A Nesbakken; K Nygaard; O Westerheim; T Mala; O C Lunde
Journal:  Eur J Surg Oncol       Date:  2002-03       Impact factor: 4.424

3.  Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer.

Authors:  M Ueno; M Oya; K Azekura; T Yamaguchi; T Muto
Journal:  Br J Surg       Date:  2005-06       Impact factor: 6.939

4.  Prognostic implications of circumferential location of distal rectal cancer.

Authors:  E García-Granero; O Faiz; B Flor-Lorente; S García-Botello; P Esclápez; A Cervantes
Journal:  Colorectal Dis       Date:  2010-03-02       Impact factor: 3.788

5.  Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer.

Authors:  H Ueno; J Murphy; J R Jass; H Mochizuki; I C Talbot
Journal:  Histopathology       Date:  2002-02       Impact factor: 5.087

6.  Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study.

Authors: 
Journal:  Radiology       Date:  2007-02-28       Impact factor: 11.105

7.  Total mesorectal excision and local recurrence: a study of tumour spread in the mesorectum distal to rectal cancer.

Authors:  N Scott; P Jackson; T al-Jaberi; M F Dixon; P Quirke; P J Finan
Journal:  Br J Surg       Date:  1995-08       Impact factor: 6.939

8.  Mesorectal excision for rectal cancer.

Authors:  J K MacFarlane; R D Ryall; R J Heald
Journal:  Lancet       Date:  1993-02-20       Impact factor: 79.321

9.  Outcomes of surgery alone for lower rectal cancer with and without pelvic sidewall dissection.

Authors:  Hirotoshi Kobayashi; Hidetaka Mochizuki; Tomoyuki Kato; Takeo Mori; Shingo Kameoka; Kazuo Shirouzu; Kenichi Sugihara
Journal:  Dis Colon Rectum       Date:  2009-04       Impact factor: 4.585

10.  Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging.

Authors:  Takashi Akiyoshi; Masashi Ueno; Kiyoshi Matsueda; Tsuyoshi Konishi; Yoshiya Fujimoto; Satoshi Nagayama; Yosuke Fukunaga; Toshiyuki Unno; Atsuhiro Kano; Hiroya Kuroyanagi; Masatoshi Oya; Toshiharu Yamaguchi; Toshiaki Watanabe; Tetsuichiro Muto
Journal:  Ann Surg Oncol       Date:  2013-08-21       Impact factor: 5.344

View more
  7 in total

1.  Neoadjuvant CapeOx therapy followed by sphincter-preserving surgery for lower rectal cancer.

Authors:  Taishi Hata; Hidekazu Takahashi; Daisuke Sakai; Naotsugu Haraguchi; Junichi Nishimura; Toshihiro Kudo; Matsuda Chu; Ichiro Takemasa; Satoh Taroh; Tsunekazu Mizushima; Yuichiro Doki; Masaki Mori
Journal:  Surg Today       Date:  2017-05-04       Impact factor: 2.549

2.  Effects of robotic rectal surgery on sexual and urinary functions in male patients.

Authors:  Shinji Ozeki; Kotaro Maeda; Tsunekazu Hanai; Koji Masumori; Hidetoshi Katsuno; Hiroshi Takahashi
Journal:  Surg Today       Date:  2015-07-22       Impact factor: 2.549

3.  Neoadjuvant treatment for locally advanced rectal cancer: a systematic review.

Authors:  Keisuke Uehara; Masato Nagino
Journal:  Surg Today       Date:  2015-07-14       Impact factor: 2.549

4.  (18)F-Fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) for the early detection of response to neoadjuvant chemotherapy for locally advanced rectal cancer.

Authors:  Junichi Nishimura; Junichi Hasegawa; Yoji Ogawa; Hideaki Miwa; Mamoru Uemura; Naotsugu Haraguchi; Taishi Hata; Hirofumi Yamamoto; Ichiro Takemasa; Tsunekazu Mizushima; Riichiro Nezu; Yuichiro Doki; Masaki Mori
Journal:  Surg Today       Date:  2015-12-28       Impact factor: 2.549

Review 5.  Transanal total mesorectal excision for rectal cancer.

Authors:  Suguru Hasegawa; Ryo Takahashi; Koya Hida; Kenji Kawada; Yoshiharu Sakai
Journal:  Surg Today       Date:  2015-06-09       Impact factor: 2.549

Review 6.  Required distal mesorectal resection margin in partial mesorectal excision: a systematic review on distal mesorectal spread.

Authors:  A A J Grüter; A S van Lieshout; S E van Oostendorp; J C F Ket; M Tenhagen; F C den Boer; R Hompes; P J Tanis; J B Tuynman
Journal:  Tech Coloproctol       Date:  2022-08-29       Impact factor: 3.699

7.  Clinicopathological outcomes of preoperative chemoradiotherapy using S-1 plus Irinotecan for T4 lower rectal cancer.

Authors:  Naohito Beppu; Hidenori Yoshie; Fumihiko Kimura; Tsukasa Aihara; Hiroshi Doi; Norihiko Kamikonya; Nagahide Matsubara; Naohiro Tomita; Hidenori Yanagi; Naoki Yamanaka
Journal:  Surg Today       Date:  2015-09-12       Impact factor: 2.549

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.